July 22, 2019
Jamie Blundell, President & COO is pleased to provide the following update CB2 Insights, part of CGOC’s public holdings:
CB2 Insights (“CB2”), part of CGOC’s public portfolio, a leading data-driven company focused on bringing Real-World Evidence driven from the point-of-care to the medical cannabis community, recently announced being selected as the exclusive research technology platform for the leading, and only independent scientific body on drugs in the UK, as part of the UK’s largest medical cannabis Pilot, named “Project TWENTY21”. Project TWENTY21 aims to enroll 20,000 patients into the Pilot and CB2 Insights was selected as the platform on which to build the patient registry and generate Real-World Evidence throughout the program. The Pilot will assess efficacy, safety, quality of life, health outcome measures and patient reported outcomes, focusing on cannabinoid therapies.
The UK represents an emerging market with immense potential but has seen major barriers to access due to limited data resources for physicians and other stakeholders. CB2 Insights’ experience in building one of the largest patient registries specific to medical cannabis in the US through its multi-state clinical operations, led to this partnership. To read the full news release issued on July 18, 2019, follow this link.
Sign up here to be included in our email blasts and receive timely updates.
For further information please contact Cannabis Growth Opportunity Corporation:
|Website: www.cgocorp.com||Investor Relations Email: firstname.lastname@example.org|
CB2 Insights has a mission to mainstream medical cannabis into traditional healthcare. We do so by gathering data and creating objective real-world evidence through our proprietary software and service brands. Using clinical management and data collection software at the point-of-care, CB2 Insights and its group of sub-brands has become a leading force behind bringing traditional healthcare protocols to the rapidly evolving global cannabis industry.
For more information please visit www.cb2insights.com